Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CX4-H52D3 | Human | Human CXCR4 Full Length Protein, Flag,His Tag (Detergent) | ![]() |
![]() ![]() |
|
CX4-H5219 | Human | Human CXCR4 / CD184 Full Length Protein (VLP) |
![]() ![]() |
||
CX4-H5269 | Human | Human CXCR4 / CD184 Protein, Fc Tag | ![]() |
![]() ![]() |
Immobilized Human CXCR4 Full Length Protein-VLP (Cat. No. CX4-H5219) at 5 μg/mL (100 μL/well) can bind Human ulocuplumab, Human IgG4 with a linear range of 1-31 ng/mL (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Plerixafor | SDZ-SID-791; JM-3100; JKL-169; AMD-3100; PLR-001; LM-3100 | Approved | Genzyme Corp | Mozobil, Mobozil, 释倍灵 | United States | Lymphoma, Non-Hodgkin; Multiple Myeloma | Genzyme Corp | 2008-12-15 | Agranulocytosis; Pulmonary Fibrosis; Rejection of organ transplantation; Respiratory Distress Syndrome, Adult; Leukopenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Osteosarcoma; Colorectal Neoplasms; Lymphopenia; Multiple Myeloma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Pulmonary Disease, Chronic Obstructive; Lymphoma; Granulomatous Disease, Chronic; Adenocarcinoma; Leukemia, Lymphocytic, Chronic, B-Cell; Anemia, Sickle Cell; WHIM syndrome; Hematopoietic stem cell transplantation (HSCT); Cystic Fibrosis; Infections; Leukemia, Myelogenous, Chronic; Wiskott-Aldrich Syndrome; Ovarian Neoplasms; Hematologic Neoplasms; Neutropenia; Bone metastases; Warts; Primary Graft Dysfunction; Coronavirus Disease 2019 (COVID-19); Fanconi Anemia; Hodgkin Disease; Pancreatic Neoplasms; Myelodysplastic Syndromes | Details |
Mavorixafor | AMD-11070; AMD-070; X4P-001; X4P-001-RD; X4P-001-LD; ABSK-081; X4P-001-IO | Approved | Genzyme Corp | XOLREMDI, Xolremdi | United States | WHIM syndrome | X4 Pharmaceuticals Inc | 2024-04-26 | HIV Infections; WHIM syndrome; Neutropenia; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Waldenstrom Macroglobulinemia; Melanoma | Details |
Motixafortide | 4F-Benzoyl-TN14003; TN-14003; TF-14016; BL-8040; BKT-140; GFH-168; 4F-benzoyl-TN-14003 | Approved | Biokine, Kyoto University | APHEXDA | United States | Hematopoietic stem cell transplantation (HSCT) | Biolinerx Ltd | 2023-09-08 | Leukemia, Myelogenous, Chronic; Hematopoietic stem cell transplantation (HSCT); Esophageal Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Hodgkin Disease; Pancreatic Neoplasms; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Aplastic; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Anemia, Sickle Cell; Adenocarcinoma | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
[68Ga]Pentixafor | [68Ga]Ga-PentixaFor; CXCR4-PET; 68Ga-PTF; [68Ga]Ga-PentixaFor PET/CT; [68Ga]Ga-PTF | Phase 3 Clinical | The University Of Iowa, Pentixapharm AG | Lymphoma, B-Cell, Marginal Zone; Cushing Syndrome; Sarcoidosis; Rejection of organ transplantation; Neuroendocrine Tumors; Multiple Myeloma; Histiocytosis, Sinus; Erdheim-Chester Disease; Histiocytic Sarcoma; Myocarditis; Lymphoma, Non-Hodgkin; Hyperaldosteronism; Central Nervous System Lymphoma | Details |
90Y-Pentixather | Phase 2 Clinical | University Of Wurzburg, Technical University Of Munich | Multiple Myeloma; Central Nervous System Lymphoma | Details | |
177Lu-Pentixather | Phase 2 Clinical | Technical University Of Munich, Nantes University Hospital, University Of Wurzburg | Leukemia; Multiple Myeloma | Details | |
Burixafor Hydrobromide | TG-0054; GP 01; GPC-100; TG-3000 | Phase 2 Clinical | TaiGen Biotechnology Co Ltd | Hematopoietic stem cell transplantation (HSCT); Hodgkin Disease; Multiple Myeloma; Prostatic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin | Details |
MSX-122 | Q-122; WZ-40; MSX-122 | Phase 2 Clinical | Altiris Therapeutics | Solid tumours; Hot Flashes | Details |
PTX-9908 | PTX-9908 | Phase 2 Clinical | Pertinax Therapeutics | Carcinoma, Hepatocellular | Details |
Ga-68-CXCR4 | Ga-68-CXCR4 | Phase 2 Clinical | Koo Foundation Sun Yat-Sen Cancer Center | Lymphoma, B-Cell | Details |
Plerixafor/Tacrolimus Hydrate | AMD3100+FK506; MRG-001(MedRegen) | Phase 2 Clinical | MedRegen LLC | Motor Neuron Disease; Cytokine Release Syndrome; Hepatitis, Alcoholic; Respiratory Tract Diseases; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Abdominal Injuries; Wounds and Injuries; Respiratory Insufficiency; Amyotrophic Lateral Sclerosis | Details |
NRP-2945 | NRP-2945; NNZ-4945 | Phase 2 Clinical | Neuren Pharmaceuticals Ltd, Calzada Ltd | Angelman Syndrome; Rett Syndrome; Lennox Gastaut Syndrome; Epilepsy, Absence; Epilepsy, Temporal Lobe; Amyotrophic Lateral Sclerosis | Details |
4-P-021 | 4P021; 4-P-021 | Phase 2 Clinical | 4P-Pharma Ltd, University of Bordeaux, Institut Pasteur De Lille | Coronavirus Disease 2019 (COVID-19) | Details |
CGT-1881 | CGT1881; CGT-1881 | Phase 2 Clinical | Cgenetech(Suzhou China) Co Ltd | Hematopoietic stem cell transplantation (HSCT); Hematologic Neoplasms; Multiple Myeloma; Lymphoma, Non-Hodgkin | Details |
AGT 103-T | AGT 103-T | Phase 1 Clinical | American Gene Technologies International Inc | HIV Infections | Details |
Balixafortide | POL-6326 | Phase 1 Clinical | Polyphor Ltd | Leukemia, Myelogenous, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Multiple Myeloma; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Metastatic breast cancer; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
JVS-100 | JVS-100; SRX-100; ACRX-100; GP-51801; GP51801 | Phase 1 Clinical | Cleveland Clinic | Heart Failure; Ischemia; Surgical Wound; Peripheral Arterial Disease | Details |
68Ga-JH12 | 68Ga-JH12 | Phase 1 Clinical | First Affiliated Hospital Of Fujian Medical University | Neoplasms | Details |
203-Lead Pentixather | Phase 1 Clinical | National Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer Center | Small Cell Lung Carcinoma; Lung Neoplasms | Details | |
212-Lead Pentixather | Phase 1 Clinical | National Institutes Of Health, National Cancer Institute, Holden Comprehensive Cancer Center | Small Cell Lung Carcinoma; Lung Neoplasms | Details | |
68Ga-Pentixather | 68Ga-Pentixather | Phase 1 Clinical | Peking Union Medical College Hospital | Multiple Myeloma | Details |
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Multiple Myeloma | Details | |
AD-214 | AD-214 | Phase 1 Clinical | Adalta Ltd | Lung Diseases, Interstitial | Details |
X-4136 | X-4136 | Clinical | X4 Pharmaceuticals Inc | Lymphoma, B-Cell; Melanoma; Uterine Cervical Neoplasms | Details |
[18F]AlF-NOTA-pentixather | Sichuan Provincial People'S Hospital | Details |
This web search service is supported by Google Inc.